THERAPEUTIC DRUG FOR FUNGAL INFECTION AND METHOD FOR TREATING FUNGAL INFECTION
Provided is a therapeutic drug for fungal infection, the drug containing human γδT cells as an active ingredient. The therapeutic agent for fungal infection has no adverse effects and tends not to be affected by drug resistance..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 21. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
TAKAZONO TAKAHIRO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-21, Last update posted on www.tib.eu: 2023-10-25, Last updated: 2023-11-03 |
|---|
| Patentnummer: |
WO2023176896 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018273122 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018273122 | ||
| 003 | DE-627 | ||
| 005 | 20231103090809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231020s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018273122 | ||
| 035 | |a (EPA)WO2023176896 | ||
| 035 | |a (EPA)88023892 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a TAKAZONO TAKAHIRO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a THERAPEUTIC DRUG FOR FUNGAL INFECTION AND METHOD FOR TREATING FUNGAL INFECTION |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-21, Last update posted on www.tib.eu: 2023-10-25, Last updated: 2023-11-03 | ||
| 520 | |a Provided is a therapeutic drug for fungal infection, the drug containing human γδT cells as an active ingredient. The therapeutic agent for fungal infection has no adverse effects and tends not to be affected by drug resistance. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KOGA SATORU |4 aut | |
| 700 | 0 | |a TANAKA YOSHIMASA |4 aut | |
| 700 | 0 | |a MUKAE HIROSHI |4 aut | |
| 700 | 0 | |a IZUMIKAWA KOICHI |4 aut | |
| 700 | 0 | |a NAKADA NANA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 21. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88023892/publication/WO2023176896A1?q=WO2023176896 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 21 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 09 | ||